It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- Kyoto Univ., Sumitomo Dainippon, Sumitomo Chemical Team Up for Research on iPS Cell Production
December 25, 2018
- Xtandi Smashes Primary Goal in Patients with mHSPC in PIII Trial
December 25, 2018
- Daiichi Sankyo Kicks Off 1st Combo Study for Its 2 AML Meds
December 21, 2018
- Fuji Pharma Invests US$50 Million in Alvotech to Boost Biosimilar Business in Japan
December 21, 2018
- ViiV’s HIV Drug Juluca Now Available in Japan
December 21, 2018
- Kowa Reps Continue Heavy GP Pitch for Parmodia in September: Anterio
December 21, 2018
- Taisho to Develop Overseas Biz in Asia and Europe through BMS’s Consumer Unit Buyout
December 21, 2018
- Fujifilm to Set Up New iPS Cell Production Facility in US, Start Operations in FY2019
December 21, 2018
- Life Science Institute Initiates Exploratory Clinical Trial of Muse Cell Product for Epidermolysis Bullosa
December 21, 2018
- Taisho to Acquire Bristol-Myers’s Consumer Health Unit
December 20, 2018
- Chugai’s Satralizumab Wins FDA Breakthrough Therapy Status
December 20, 2018
- ROS1/TRK Inhibitor Entrectinib Filed in Japan: Chugai
December 20, 2018
- Toray Sues Sawai, Fuso over Use Patent for Remitch OD Tablets
December 20, 2018
- Shionogi Licenses Cognitive Disorders Treatment Candidate from Tetra
December 20, 2018
- Shonan iPark Sets Up Consortium for Commercializing Disease Prevention
December 20, 2018
- Otezla Reduces Oral Ulcers in Japanese Behcet’s Disease Patients in PIII Study: Celgene
December 20, 2018
- Takeda Likely to Make NYSE Debut on Christmas Eve
December 19, 2018
- Bristol-Myers, Eisai Unit Ink I/O Collaboration
December 19, 2018
- Daiichi Sankyo Grants ROS1/NTRK Inhibitor Rights to AnHeart
December 19, 2018
- Shionogi Earns CHMP OK for Naldemedine
December 19, 2018
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…